Sermorelin news and clinical trials

Carolina Infusion, LLC initiated a class II recall of various semaglutide and semaglutide/cyanocobalamin injectables. The firm cited a lack of assurance of sterility related to the use of bacteriostatic water and processing equipment.

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

A case report describes a 62-year-old bodybuilder who developed dysphagia from anterior cervical osteophytes, raising the hypothesis that his 20-year history of exogenous growth hormone and GH secretagogue use may have contributed to significant bone growth.

A review of peptides modulating the GH-IGF-1 axis highlights the significant gap between clinical evidence and unregulated self-administration protocols. Clinicians are advised to recognize potential adverse effects like endocrine disturbances, fluid retention, and metabolic issues.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

A critical review of peptide use in sports concludes that while peptides are marketed as safer alternatives to steroids for bodybuilding, long-term safety data is lacking and the unregulated supply chain poses significant health risks. Evidence for performance enhancement is limited.

A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.

Researchers developed and validated a nano-LC quadrupole/orbitrap mass spectrometry method to detect growth hormone-releasing hormone and analogs like sermorelin and CJC-1295 in urine. The method achieved limits of detection at or below 0.5 ng/mL, meeting WADA anti-doping testing requirements.